Hayward, CA-based therapeutic oncology company RefleXion Medical recently closed on a $105 million equity raise.
The new funds will allow the company to extend commercialization of its U.S.-cleared Scintix biology-guided radiotherapy system for treating all stages of indicated solid tumor cancers, including metastatic disease, RefleXion said.
Funding was led by The Rise Fund. Other investors included Ally Bridge, Pfizer Ventures, and Johnson & Johnson Innovation, the company noted.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
